Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prevention of Meningococcal Infection”

48 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 48 results

Post-approval studies (Phase 4)Study completedNCT00271479
What this trial is testing

Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine

Who this might be right for
Infections, MeningococcalMeningitis, Meningococcic
Epicentre 720
Large-scale testing (Phase 3)Study completedNCT00944034
What this trial is testing

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis Vaccines 1,588
Testing effectiveness (Phase 2)Study completedNCT00488683
What this trial is testing

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Who this might be right for
Meningococcal Disease
Novartis Vaccines 216
Testing effectiveness (Phase 2)Study completedNCT00262002
What this trial is testing

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

Who this might be right for
Prevention of Meningococcal Disease
Novartis Vaccines 601
Testing effectiveness (Phase 2)Study completedNCT01367158
What this trial is testing

Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis Vaccines 440
Large-scale testing (Phase 3)Study completedNCT00310674
What this trial is testing

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

Who this might be right for
Prevention of Meningococcal Infection
Novartis 150
Testing effectiveness (Phase 2)Study completedNCT00601731
What this trial is testing

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

Who this might be right for
Meningococcal Disease
Novartis Vaccines 382
Large-scale testing (Phase 3)Study completedNCT00197275
What this trial is testing

Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants

Who this might be right for
TetanusHepatitis BHaemophilus Influenzae Type b+2 more
GlaxoSmithKline 800
Post-approval studies (Phase 4)Study completedNCT00310700
What this trial is testing

Kinetics of B Cell Response in Infants Menjugate Vaccination

Who this might be right for
Prevention of Meningococcal Infection
Novartis 75
Testing effectiveness (Phase 2)Study completedNCT00381615
What this trial is testing

Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Who this might be right for
Healthy
Novartis Vaccines 147
Large-scale testing (Phase 3)Study completedNCT00847145
What this trial is testing

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Who this might be right for
Meningococcal Disease
Novartis Vaccines 2,249
Large-scale testing (Phase 3)Study completedNCT01423084
What this trial is testing

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis 344
Testing effectiveness (Phase 2)Study completedNCT01027351
What this trial is testing

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Who this might be right for
Meningococcal Disease
Novartis Vaccines 163
Post-approval studies (Phase 4)Study completedNCT02724046
What this trial is testing

Ciprofloxacin for the Prevention of Meningococcal Meningitis

Who this might be right for
Meningitis, Meningococcal
Epicentre 300
Testing effectiveness (Phase 2)Study completedNCT00560313
What this trial is testing

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Who this might be right for
Meningococcal Disease
Novartis Vaccines 54
Not applicableNot Yet RecruitingNCT07671014
What this trial is testing

Metagenomic Analysis of the Pharynx in High Risk Partners

Who this might be right for
GonorrheaNeisseria GonorrheaNeisseria Meningitidis+1 more
Guy's and St Thomas' NHS Foundation Trust 100
Large-scale testing (Phase 3)Study completedNCT00136604
What this trial is testing

Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

Who this might be right for
Whole Cell PertussisHaemophilus Influenzae Type bHepatitis B+3 more
GlaxoSmithKline 617
Testing effectiveness (Phase 2)Study completedNCT00262028
What this trial is testing

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

Who this might be right for
Prevention of Meningococcal Disease
Novartis Vaccines 910
Testing effectiveness (Phase 2)Study completedNCT00135486
What this trial is testing

Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 500
Large-scale testing (Phase 3)Study completedNCT00345579
What this trial is testing

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Who this might be right for
Haemophilus Influenzae Type bNeisseria Meningitidis
GlaxoSmithKline 4,432
Next Page